Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RAP-219 · 5 trials · 8 indications
Median percent change in seizure frequency and ≥ 50% seizure frequency reduction responder rates
The YMRS is a clinician administered scale that consists of 11 items used to assess the severity of manic symptoms (total scores range from 0 to 60). The higher the YMRS score, the more severe the subject's symptoms of mania.
Change in long episode frequency per 28-day period during the treatment period compared to baseline
| Arm | Type | Description |
|---|---|---|
| Active Arm- Medium Dose | EXPERIMENTAL | RAP-219 daily tablets administered orally |
| Active Arm-Low Dose | EXPERIMENTAL | RAP-219 daily tablets administered orally |
| Placebo | PLACEBO_COMPARATOR | Inert comparator matching the active treatment |
| Active Arm- High Dose | EXPERIMENTAL | RAP-219 daily tablets administered orally |
| RAP-219 | EXPERIMENTAL | - |
| Active Arm | EXPERIMENTAL | Treatment with RAP-219 |
| Name | Type | Description |
|---|---|---|
| RAP-219 | DRUG | RAP-219 medium dose tablets administered orally daily |
| Placebo | OTHER | Matching placebo tablets administered orally |
Inclusion Criteria: 1. Age 18 - 75 2. BMI 18-45 kg/m2 3. Diagnosis of focal epilepsy for ≥24 months prior to Visit 1 4. Report from at least 1 brain MRI or CT scan and 1 EEG study, each completed within 10 years prior to Visit 1, consistent with focal epilepsy diagnosis 5. Concomitant use of betwee...
RAP-219 is an investigational small molecule being developed for focal onset seizures, focal epilepsy, and bipolar 1 disorder. It is currently in Phase 2 and Phase 3 clinical trials for these conditions.
RAP-219 targets the RAP protein. It is a small molecule being studied for its potential to treat neurological and psychiatric conditions, including focal epilepsy and bipolar 1 disorder.
RAP-219 is being developed by Rapport Therapeutics, Inc., a biopharmaceutical company. The company's stock trades under the ticker symbol RAPP.
RAP-219 is in Phase 2 and Phase 3 clinical development. It is not approved by the FDA and remains investigational. Active trials include a Phase 2 study in bipolar 1 disorder and a Phase 3 study in focal seizures.
RAP-219 is being studied in several trials. NCT06377930 is a completed Phase 2 study in refractory focal epilepsy. NCT07046494 is a recruiting Phase 2 study in bipolar 1 disorder. NCT07219407 is a recruiting long-term Phase 2 study in focal onset seizures, and NCT07563881 is a recruiting Phase 3 study in focal seizures.
No alternative names for RAP-219 have been disclosed. It is identified solely by the code name RAP-219 in clinical trials and development programs.